Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats

[1]  M. Abecassis,et al.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases , 2019, Clinical Liver Disease.

[2]  J. L. Hansen,et al.  Role of age, Rho‐kinase 2 expression, and G protein‐mediated signaling in the myogenic response in mouse small mesenteric arteries , 2018, Physiological reports.

[3]  P. Olinga,et al.  Polymeric microspheres for the sustained release of a protein-based drug carrier targeting the PDGFβ-receptor in the fibrotic kidney. , 2017, International journal of pharmaceutics.

[4]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[5]  Menaka C Thounaojam,et al.  Characterization of pressure-mediated vascular tone in resistance arteries from bile duct-ligated rats , 2017, Oncotarget.

[6]  J. Bosch,et al.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases , 2017, Hepatology.

[7]  C. Strassburg,et al.  Statins improve NASH via inhibition of RhoA and Ras. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[8]  C. Strassburg,et al.  Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension , 2016, PloS one.

[9]  P. Boor,et al.  The role of PDGF-D in healthy and fibrotic kidneys. , 2016, Kidney international.

[10]  C. Strassburg,et al.  Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis , 2015, Front. Physiol..

[11]  C. Strassburg,et al.  Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension , 2015, Scientific Reports.

[12]  C. Strassburg,et al.  Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis , 2015, PloS one.

[13]  C. Strassburg,et al.  Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis , 2015, Gut.

[14]  P. Boor,et al.  Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis , 2015, Scientific Reports.

[15]  Yonghyun Kim,et al.  ROCK Inhibition Facilitates In Vitro Expansion of Glioblastoma Stem-Like Cells , 2015, PloS one.

[16]  D. Rockey,et al.  Renal dysfunction in cirrhosis , 2015, Current opinion in gastroenterology.

[17]  J. Trebicka,et al.  The carbon tetrachloride model in mice , 2015, Laboratory animals.

[18]  G. Kristiansen,et al.  Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[19]  S. Friedman,et al.  β-PDGF Receptor Expressed by Hepatic Stellate Cells Regulates Fibrosis in Murine Liver Injury, but Not Carcinogenesis , 2015, Journal of hepatology.

[20]  M. Bernardi,et al.  Hyponatremia in Patients with Cirrhosis of the Liver , 2014, Journal of clinical medicine.

[21]  M. Perazella,et al.  Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury , 2014, Hepatology.

[22]  M. Davidson,et al.  Selective regulation of cytoskeletal tension and cell-matrix adhesion by RhoA and Src. , 2014, Integrative biology : quantitative biosciences from nano to macro.

[23]  W. Jiménez,et al.  Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. , 2014, Journal of hepatology.

[24]  J. Nattermann,et al.  Angiotensin‐II type 1 receptor‐mediated Janus kinase 2 activation induces liver fibrosis , 2014, Hepatology.

[25]  M. Olson,et al.  Rho-associated coiled-coil containing kinases (ROCK) , 2014, Small GTPases.

[26]  R. Schwabe,et al.  Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.

[27]  T. Walther,et al.  Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. , 2013, Gastroenterology.

[28]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[29]  P. Boor,et al.  Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. , 2013, The American journal of pathology.

[30]  T. Sauerbruch,et al.  HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.

[31]  F. Wong,et al.  Recent advances in our understanding of hepatorenal syndrome , 2012, Nature Reviews Gastroenterology &Hepatology.

[32]  M. A. Sheddi.  A clinicopathological study , 2012 .

[33]  Ruchi Bansal,et al.  Peptide-modified albumin carrier explored as a novel strategy for a cell-specific delivery of interferon gamma to treat liver fibrosis. , 2011, Molecular pharmaceutics.

[34]  D. Schuppan,et al.  Novel engineered targeted interferon‐gamma blocks hepatic fibrogenesis in mice , 2011, Hepatology.

[35]  J. Prakash,et al.  Reduction of Fibrogenesis by Selective Delivery of a Rho Kinase Inhibitor to Hepatic Stellate Cells in Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.

[36]  J. Prakash,et al.  Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632 , 2011, Pharmaceutical Research.

[37]  L. E. Rajagopalan,et al.  TGF-β1 mediated activation of Rho kinase induces TGF-β2 and endothelin-1 expression in human hepatic stellate cells. , 2011, Journal of hepatology.

[38]  P. Pacaud,et al.  The role of Rho protein signaling in hypertension , 2010, Nature Reviews Cardiology.

[39]  Christian Melot,et al.  Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites , 2010, Hepatology.

[40]  V. Paradis,et al.  The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[41]  F. Nevens,et al.  Role of β3‐adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis , 2009, Hepatology.

[42]  R. Kok,et al.  Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. , 2008, Journal of the American Society of Nephrology : JASN.

[43]  W. Welch,et al.  ROCK and PRK‐2 mediate the inhibitory effect of Y‐27632 on polyglutamine aggregation , 2008, FEBS letters.

[44]  T. Sauerbruch,et al.  Mechanisms of extrahepatic vasodilation in portal hypertension , 2008, Gut.

[45]  F. Lammert,et al.  Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats , 2007, Hepatology.

[46]  S. Nishikawa,et al.  A ROCK inhibitor permits survival of dissociated human embryonic stem cells , 2007, Nature Biotechnology.

[47]  T. Sauerbruch,et al.  Vascular dysfunction in human and rat cirrhosis: Role of receptor‐desensitizing and calcium‐sensitizing proteins , 2007, Hepatology.

[48]  K. Jakobs,et al.  Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. , 2006, Gastroenterology.

[49]  T. Sauerbruch,et al.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis , 2006, Gut.

[50]  T. Sauerbruch,et al.  Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats , 2003, European journal of clinical investigation.

[51]  D. Meijer,et al.  The preferential homing of a platelet derived growth factor receptor-recognizing macromolecule to fibroblast-like cells in fibrotic tissue. , 2003, Biochemical pharmacology.

[52]  H. Nawata,et al.  A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. , 2001, Journal of hepatology.

[53]  Fumio Matsumura,et al.  Distinct Roles of Rock (Rho-Kinase) and Mlck in Spatial Regulation of Mlc Phosphorylation for Assembly of Stress Fibers and Focal Adhesions in 3t3 Fibroblasts , 2000, The Journal of cell biology.

[54]  S. Seki,et al.  ROCK inhibitor Y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. , 1999, Biochemical and biophysical research communications.

[55]  X. Q. Chen,et al.  The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton , 1996, Molecular and cellular biology.

[56]  F. Trevisani,et al.  The hemodynamic status of preascitic cirrhosis: An evaluation under steady‐state conditions and after postural change , 1992, Hepatology.